Regeneron Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ shows slight gains of 3.53%. Dividends of €0.94 are taken into consideration when calculating the performance. This prediction currently runs until 02.02.27. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.867% | 1.867% |
| iShares Core DAX® | -3,99 % | -2,81 % |
| iShares Nasdaq 100 | 0,35 % | -0,75 % |
| iShares Nikkei 225® | -3,85 % | 4,23 % |
| iShares S&P 500 | 0,30 % | 0,38 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
09.06.25
09.06.26
17:03
Regeneron Pharmaceuticals Inc.
31.03.25
31.03.26
17:03
Regeneron Pharmaceuticals Inc.
24.10.24
24.10.25
25.10.25
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25
Regeneron Pharmaceuticals Inc.
17.06.24
17.06.25
18.06.25

